Regulation of Tumor Lactate Metabolism by Targeting Glycolysis and Mitochondrial OXPHOS for Tumor Metastasis Inhibition

Huangjin Lai,Xiao Wu,Juan Tan,Xiaodong Zhou,Chunyan Liao,Shiyong Zhang
DOI: https://doi.org/10.1021/acs.iecr.3c01051
2023-01-01
Industrial & Engineering Chemistry Research
Abstract:Regulation of tumor lactate metabolism is a promisingstrategyfor tumor metastasis inhibition but remains challenging. Herein, anew nanodrug that can regulate tumor lactate metabolism by targetingboth glycolysis and mitochondrial oxidative phosphorylation (OXPHOS)was developed by loading 3-(3-pyridyl)-1-(4-pyridyl)-2-propen-1-one(3PO) in the cross-linked sodium lipoic acid vesicle (3PO@cLANa).After entering cells, cLANa dissociated into lipoic acid/dihydrolipoicacid (LA/DHLA) and released 3PO. 3PO suppressed glycolysis throughinhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3and LA/DHLA enhanced mitochondrial OXPHOS through inhibiting pyruvatedehydrogenase kinase 1. Since glycolysis and mitochondrial OXPHOSare two major metabolic pathways for lactate generation, 3PO@cLANaeffectively regulated the production of lactate. In vivo results disclosedthat 3PO@cLANa achieved a 45.9% reduction of lactate in the B16F10melanoma tumor model and only 11 of the metastasis foci were observedin the lungs, 1.55-fold lower than that of dacarbazine (17 metastasisfoci), the first-line antitumor drug of melanoma. When combined with & alpha;-PD1, the lung metastasis foci decreased further to 5. Thetumor lactate metabolism-regulated nanodrug with both glycolysis andmitochondrial OXPHOS targeting holds clinical potential.
What problem does this paper attempt to address?